Tanguy Seiwert, MD

Tanguy Seiwert, MD, associate program director for Head and Neck Cancer, assistant professor of Medicine, The University of Chicago Medicine, discusses the activity of immunotherapy in head and neck cancers. Seiwert says in general, immunotherapies produce a response rate of between 20- to 25%, 1 in 4 patients respond, and the treatment type is equally effective in both HPV-positive and HPV-negative disease.

Videos

Seiwert says in general, immunotherapies produce a response rate of between 20- to 25%, 1 in 4 patients respond, and the treatment type is equally effective in both HPV-positive and HPV-negative disease.

Dr. Tanguy Seiwert on the Increasing Efficacy of Immunotherapies in Head and Neck Cancer

Seiwert believes this study presents a new class of active agents for head and neck cancer, and he and his colleagues hope to eventually prolong survival. Pembrolizumab is the first active therapy since cetuximab, so Seiwert and his colleagues have high hopes for future trials.

Going forward, Seiwert and his team have many questions to answer. They do not yet know how survival will be impacted, or whether to add a biomarker.

Tanguy Seiwert, MD, assistant professor of medicine, associate leader, Head and Neck Cancer Program, University of Chicago, discusses the significance of pembrolizumab in head and neck cancer.

Tanguy Seiwert, MD | Authors

Articles

Dr. Tanguy Seiwert on the Increasing Efficacy of Immunotherapies in Head and Neck Cancer

Significance of Pembrolizumab in Head and Neck Cancer